Wendy Armstrong, MD, FIDSA is Professor of Medicine/Infectious Diseases and the Division Head at the University of Colorado School of Medicine. Her research interests are in innovative methods of care delivery to vulnerable populations living with HIV and in expanding the ID/HIV workforce. She has published more than 100 journal articles and book chapters related to these topics. She is the President-elect for the Infectious Disease Society of America and is a past Chair of the HIV Medicine Association.

Paul G Auwaerter is the Sherrilyn and Ken Fisher Professor of Medicine at the Johns Hopkins University School of Medicine and Director of the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases.

He serves as the Executive Director of the Johns Hopkins Point of Care-Information Technology (POC-IT) Center, producing the Johns Hopkins Antibiotic Guide (ABX), JH HIV, JH Osler, JH Psychiatry, and JH Diabetes Guides. Dr. Auwaerter serves as Editor-in-Chief of the ABX Guide. Over the last 20 years, it has become a standard reference for ID-related clinical decision support and rational antimicrobial management. Dr. Auwaerter’s research and clinical interests include improving the diagnosis, care, and prevention of Lyme disease and other tick-borne infections, as well as fevers of unknown origin, surgical infections, Epstein-Barr virus, and antibiotic resistance. He has published over 125 articles and 30 textbook chapters.

He has served for 19 years as the Clinical Director of the Johns Hopkins Division of Infectious Disease. He is also a Past President of the Infectious Diseases Society of America (IDSA), the largest professional society worldwide related to infectious diseases. In 2025, Dr. Paul Auwaerter received the University’s Inaugural Osler Award for Clinical Excellence, recognizing his contributions to patient care, education, and innovation at Johns Hopkins.

Dr Isaac Bogoch is a Professor at the University of Toronto in the Department of Medicine, and an Infectious Diseases specialist at the Toronto General Hospital with a focus on tropical diseases, HIV, and general infectious diseases. He completed medical school and Internal Medicine residency training at the University of Toronto, and then specialized in Infectious Diseases at Harvard University. He holds a Master’s Degree in Epidemiology from the Harvard School of Public Health, and has completed fellowships in both Tropical Infectious Diseases and HIV care. Dr. Bogoch works at the intersection of clinical medicine, epidemiology, public health, health security and policy. He divides his clinical and research efforts between Toronto and several countries in Africa and Asia. His work focuses on reducing the impact of emerging infectious diseases like mpox, viral hemorrhagic fevers, and HIV, while also developing strategies to enhance the quality of medical care in low-resource settings.

Helen Boucher, MD, is the Dean and Professor of Medicine at Tufts University School of Medicine and Chief Academic Officer of the Tufts Medicine Health System. An active Infectious Diseases physician, she was previously Chief of the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, and Director of the Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance (Levy CIMAR).

Dr Boucher’s clinical interests include infections in immunocompromised patients and S. aureus infections. Her research interests focus on S. aureus and the development of new anti-infective agents. She is the Chair of the National Institutes of Health Antibacterial Resistance Leadership Group Innovations Working Group and serves on the Executive and Steering Committees. Dr. Boucher is the published in such journals as The New England Journal of Medicine, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, and The Annals of Internal Medicine. She previously served as Editor of Antimicrobial Agents and Chemotherapy, and currently is Editor of the Sanford Guide to Antimicrobial Therapy, and Infectious Diseases Clinics of North America.

In 2015, Dr. Boucher was appointed a voting member of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB), and elected Treasurer of the Infectious Diseases Society of America (IDSA). She was awarded the IDSA Society Citation Award in October 2015 and the Maxwell Finland Award in 2022. In 2023, she became an Honorary Fellow, Royal College of Physicians of Ireland the highest award the Royal College of Physicians of Ireland can confer. Dr. Boucher serves as Chair of the Board of Trustees of The College of the Holy Cross is a member of the Physicians of Tufts Medical Center.

Dr Kelly Cawcutt, MD, MS, FACP, FIDSA, FCCM, FSHEA is an Associate Professor of Medicine and board certified in Critical Care Medicine and Infectious Diseases at University of Nebraska Medical Center in Omaha. She is the Medical Director of Acute Care Quality, Senior Director of Infection Control and Hospital Epidemiology for Nebraska Medicine; and Co-Director of Digital Innovation and Social Media Strategy for the Infectious Diseases Division of UNMC. Nationally, she is involved with the Infectious Diseases Society of America (IDSA), the Society of Critical Care Medicine (SCCM), and the Society for Healthcare Epidemiology of America (SHEA). Dr. Cawcutt’s research interests include hospital-acquired infections (HAIs), with significant interest in sepsis and HAIs within Intensive Care Units; quality improvement within acute care settings, and faculty development through social media and leadership development.

Charles L. Daley, MD, is Chief of the Division of Mycobacterial and Respiratory Infections at National Jewish Health (NJH) and Professor of Medicine at NJH, the University of Colorado School of Medicine, and Icahn School of Medicine at Mount Sinai. Dr. Daley has served on and chaired expert panels for the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Infectious Diseases Society of America and American Thoracic Society. He chaired the multi-society sponsored revision of the guidelines for the treatment of pulmonary nontuberculous mycobacterial infections. For his work with global MDR-TB control he was awarded the World Lung Health Award by the American Thoracic Society. He was previously Associate Editor of the American Journal of Respiratory and Critical Care Medicine and The European Respiratory Journal and is now Associate Editor for Frontiers in Tuberculosis. His academic interests include clinical and translational research related to TB, NTM and bronchiectasis.

Carlos del Rio, MD is the H. Cliff Sauls, MD Distinguished Professor of Medicine and Chair of the Department of Medicine at Emory University School of Medicine. He is also Professor of Global Health and Epidemiology at the Rollins School of Public Health. Dr. del Rio is co-Director of the Emory Center for AIDS Research and co-PI of the Emory Vaccine and Treatment Evaluation Unit. A native of Mexico where he attended medical school graduating with honors in 1983. He did his Medicine and Infectious Diseases training at Emory. In 1989 he returned to Mexico where he was Executive Director of the National AIDS Council. In 1996 Dr. del Rio returned to Emory where he is involved in patient care, teaching and research. Dr. del Rio has had multiple leadership positions at Emory including Chief of the Emory Medical Service at Grady Memorial Hospital (2001 – 2009), chair of the Hubert Department of Global Health (2009 – 2019), Executive Associate Dean for Emory at Grady (2019 – 2023) and interim Dean of Emory University School of Medicine (2023 – 2024). Dr. del Rio’s research focuses on the early diagnosis, access to care, engagement in care, compliance with antiretrovirals and the prevention of HIV infection. He has worked for over a decade with hard-to-reach populations including with persons who use substances to improve outcomes of those infected with HIV and to prevent infection with those at risk. He is also interested in the translation of research findings into practice and policy. His international work includes collaborations in the country of Georgia, Ethiopia, Vietnam, Mexico, Kenya and Thailand. He has also worked on emerging infections such as pandemic influenza and was a member of the WHO Influenza A(H1N1) Clinical Advisory Group and of the CDC Influenza A(H1N1) Task Force during the 2009 pandemic. He is the Immediate Past President of the Infectious Diseases Society of America and the past chair of the PEPFAR Scientific Advisory Committee. del Rio was elected to the National Academy of Medicine in 2013 and elected as the Academy’s International Secretary in 2020 and reelected in 2024. He was also elected to the American Academy of Arts and Sciences in 2022. During the COVID-19 pandemic Dr. del Rio was a leader locally and nationally, doing research, developing policies, writing scientific publications, and making countess media appearances. Dr. del Rio advised municipal, state, and national leaders and also served on the national advisory committee of the COVID Collaborative, which focuses on developing consensus recommendations and engaging with U.S. leaders on effective policy and coronavirus response. Dr. del Rio was named as one of the “50 most trusted experts” and recognized by the HHS Secretary as a “Trusted Messenger”.

Dr Daniel Diekema is Vice Chair for Research and Director of the Division of Infectious Diseases in the Department of Medicine at Maine Medical Center in Portland, Maine. He is also a Professor Emeritus of Internal Medicine at the University of Iowa, where he served as a director for the Division of Infectious Diseases from 2010-2021. Dr. Diekema received his MD at Vanderbilt University in 1989. He did his residency in internal medicine at the University of Virginia (1989-1992). He did his fellowships in infectious diseases (1992-1995) and medical microbiology (1998-2000) at the University of Iowa. Also while at the University of Iowa, he received his master of science in preventive medicine. As a hospital epidemiologist, infectious diseases clinician and a clinical microbiologist, Dr. Diekema has studied and published extensively on the epidemiology of antimicrobial resistance and health care-associated infections. Dr. Diekema is a past president of the Society for Healthcare Epidemiology of America, and was also a member and co-chair of the CDC Healthcare Infection Control Practices Advisory Committee.

Dr Goff is an Infectious Diseases Clinical Pharmacist, Professor of Pharmacy Practice and Antibiotic Stewardship Ambassador for The Ohio State University (OSU) Global One Health Institute in Columbus Ohio, USA. She is an awarding winning global “change maker” in infectious diseases. Dr. Goff is one of twenty-five global health experts selected by the World Health Organization (WHO) to implement antibiotic stewardship programs in low middle-income countries. Dr. Goff is the Program Director for the Train the Trainer Antibiotic Stewardship Mentoring Program founded in 2012 with South African pharmacists. Her program continues to expand to include neonatal ASP and other countries including Lebanon and six Latin American countries in collaboration with country experts and neonatal experts at Nationwide Children’s Hospital in Columbus OH. She received the OSU 2019 Distinguished International Outreach and Engagement Award for her global work and the 2017 American College of Clinical Pharmacy Global Health Award. Dr. Goff is the Principal Investigator on the first US study with private practice dentists to assess their antibiotic use and provide guidance on the use of antibiotics in dentistry. Dr. Goff speaks to dental study clubs, dental schools, the FDI World Dental Federation and US Dental CE Academy providing antibiotic stewardship education to over 3,800 dental providers in over 80 countries. Her TEDx talk titled antibiotics “just in case” there’s infection has over 28,500 views on YouTube. She uses X (Twitter) (@idpharmd) to connect with her 10,000 followers. She has 150 publications and 50 grants.

Dr Andy Hale received his undergraduate education at Middlebury College, then went to medical school at Tufts University School of Medicine. He completed internal medicine residency, chief residency, and infectious diseases fellowship at Beth Israel Deaconess Medical. He is now an associate professor and ID physician at the University of Vermont Medical Center. He is the course director of cardiac, respiratory, and renal pathophysiology at UVM College of Medicine, Infectious Diseases: past, present, and future at Middlebury College, and Comparative Physiology at Mount Desert Island Biological Laboratory. He is an associate program director for the internal medicine residency at UVM. His main research interests are pragmatic studies to answer common clinical dilemmas in ID.

Dr Kimberly Hanson is a Professor of Medicine and Pathology at the University of Utah (U of U). Administratively, she serves as the Director of the Immunocompromised Host Infectious Diseases Service for U of U Health and is Director of the Mycology Section within ARUP Laboratories. Her clinical and research interests involve the development and validation of novel diagnostic tests with a focus on opportunistic infections.

Olivia Kates is Assistant Professor of Medicine and Bioethics at Johns Hopkins, Associate Director for Ethics and Qualitative Research at the Johns Hopkins Transplant Research Center, and Editor of the recurring series Ethics Rounds in the journal Clinical Infectious Diseases. She sees patients with infectious complications of immunosuppression from transplantation and chemotherapy and studies a wide range of ethical issues in transplantation and infectious diseases including liver transplantation for people who use alcohol, xenotransplantation, antimicrobial stewardship, public health policy, and her favorite – vaccines.

Dr Carl LeBuhn completed medical school, internal medicine residency, chief residency, and infectious diseases fellowship at the University of Iowa. He spent three years on the teaching faculty at the University of Iowa before entering private practice in Paducah, Kentucky in June of 2000. For the past 21 years he has has provided inpatient and outpatient general infectious diseases consultations for western Kentucky and southern Illinois. He has clinical privileges at Baptist Health Paducah, ContinueCare Hospital at Baptist Health Paducah, and Mercy Health Paducah. He and his partner provide HIV/AIDS care to approximately 400 patients through LivWell a federally funded HIV/AIDS organization. He is currently the chair of the Paducah Independent Schools Board of Education and has served on the Board since 2005.

Dr Marrazzo was appointed as the Chief Executive Officer of the Infectious Disease Society of America in January, 2026. She was the sixth Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (2023-2025), and previously was Professor of Medicine and Director of the Division of Infectious Diseases at the University of Alabama at Birmingham School of Medicine. She was elected to the National Academy of Medicine in 2024. She has a broad research portfolio that includes the relationships between the vaginal microbiome and female reproductive tract infections, HIV pre-exposure prophylaxis, hormonal contraception, and risk of STI/HIV acquisition.

Anton Peleg is a Professor of Infectious Diseases and Microbiology, Director of the Department of Infectious Diseases at The Alfred Hospital and Monash University, Director of the Centre to Impact Antimicrobial Resistance (AMR), Monash University, and Theme Leader for Infection and Immunity at the Monash Academic Health Research and Translational Centre. He has also recently been elected as a Fellow of the Australian Academy of Health and Medical Sciences.

He completed his infectious diseases clinical training in Australia in 2005 and then went to the USA for four years and trained at the Harvard-affiliated hospitals; Beth Israel Deaconess Medical Center and Massachusetts General Hospital. He completed a Masters of Public Health at Harvard School of Public Health, and also completed a PhD in Infectious Diseases and Microbiology with a focus on AMR and microbial genomics. He returned to Australia in 2010 as a clinician-scientist and built a large research program that spans fundamental, translational and clinical research.

His research interests are in hospital-acquired infections, AMR and novel solutions, bacteriophage therapy, bacterial genomics, mechanisms of pathogenesis and infections in immunocompromised hosts. He is the lead investigator on numerous AMR projects that focus on hospital, community, aged care, and regional (Pacific Island countries) settings. He is also an active clinician working in the area of transplant infectious diseases and hospital-acquired infections. He has received numerous national and international awards for his advanced research and contribution to Infectious Diseases and Microbiology.

Dr Ilan Schwartz is an Associate Professor and Infectious Diseases physician and researcher at Duke University. His clinical focus is on preventing, diagnosing, and managing infections after transplantation, and his research focuses on dimorphic fungal pathogens. He serves on the Board of Directors of the Mycoses Study Group Education & Research Consortium and is an Editor of Clinical Infectious Diseases and Mycoses.

Arjun Srinivasan currently serves as the Deputy Chief Medical Officer at The Joint Commission. He received his undergraduate degree from Davidson College and a medical degree from Vanderbilt University. He did residency training in Internal Medicine and a fellowship in Infectious Diseases at The Johns Hopkins Hospital. Following his training, he joined the faculty at Johns Hopkins where he served as the Associate Hospital Epidemiologist and the founding director of the Johns Hopkins Antibiotic Stewardship Program. He left Johns Hopkins for the Centers for Disease Control and Prevention, where he spent 22 years working in the Division of Healthcare Quality Promotion. His areas of expertise at the CDC included outbreak investigations, healthcare associated infections and antimicrobial resistance. He had a special focus on hospital antibiotic stewardship where he helped lead efforts that led to national implementation of stewardship programs in US hospitals. He is board certified in Infectious Diseases and is an adjunct faculty member in the Infectious Diseases Division at Emory University. He has published more than 150 articles in peer reviewed journals.

H. Keipp B. Talbot, MD, MPH, FIDSA is a Professor of Medicine and Health Policy within the Division of Infectious Diseases at Vanderbilt University Medical Center. She also holds the Vaccinology Research Directorship. As a dual appointee in Medicine and Health Policy, Dr. Talbot has played a pivotal role in the evaluation of viral respiratory diseases in adults and the evaluation of new and existing vaccines in older adults to improve immunization policy and vaccine development. Her goal is to continue to evaluate the use and effectiveness of vaccines, with a focus on prevention of infection and morbidity in adults. Dr. Talbot began her career by investigating the presentation of influenza in hospitalized adults. Her recent work has contributed to our understanding of the epidemiology of SARS-CoV-2, influenza, and respiratory syncytial virus. Dr. Talbot completed her tenure as Chair of the Advisory Committee on Immunization Practices (ACIP) in June 2025. During her 7 years on ACIP, she also served as the chair of the ACIP’s Influenza Vaccine Work Group and co-chair of the COVID-19 Vaccine Safety Technical Work Group. She has authored more than 280 manuscripts. Her work has informed national policy on the implementation of enhanced influenza vaccines for older adults, the use of pneumococcal vaccines in the setting of changing epidemiology, and COVID-19 vaccine introduction and use. Dr. Talbot currently co-leads the Tennessee Emerging Infections Program at Vanderbilt, which works to better understand viral respiratory disease epidemiology and inform vaccine policy.

Thomas R. Talbot, MD, MPH, FSHEA, FIDSA, is a Professor of Medicine in the Division of Infectious Diseases within the Department of Medicine and serves as the Chief Hospital Epidemiologist for Vanderbilt University Medical Center. He is a recognized expert in the field of healthcare epidemiology and infection prevention and has more than 130 publications in peer-reviewed journals, with original research studies focusing on healthcare personnel vaccination, healthcare-associated infection (HAI) surveillance, and improving hand hygiene as a tool to drive a culture of safety. He has served as a member of the Centers for Disease Control and Prevention's Healthcare Infection Control Practices Advisory Committee (HICPAC) and on the Board of Directors for the Society for Healthcare Epidemiology of America (SHEA), serving as the Vice-President in 2022, President-Elect in 2023, and President in 2024. At VUMC, Dr. Talbot is responsible for the development of operational policies and practices to prevent HAIs and the spread of highly concerning pathogens in the healthcare setting, the monitoring and surveillance of HAI process and outcome measures, and the implementation of quality improvement efforts to reduce patient harm from HAIs.